Reimbursement in the context of precision oncology approaches in metastatic breast cancer

• Verfasst von: Pixberg, Constantin Frederic [VerfasserIn]
• Verfasst von: Schulze, Markus [VerfasserIn]
• Verfasst von: Buschhorn, Lars [VerfasserIn]
• Verfasst von: Suppelna, Jan Philip [VerfasserIn]
• Verfasst von: Mock, Andreas [VerfasserIn]
• Verfasst von: Hlevnjak, Mario [VerfasserIn]
• Verfasst von: Heublein, Sabine [VerfasserIn]
• Verfasst von: Schumacher-Wulf, Eva [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Titel: Reimbursement in the context of precision oncology approaches in metastatic breast cancer
• Titelzusatz: challenges and experiences
• Verf.angabe: Constantin Pixberg, Markus Schulze, Lars Buschhorn, Jan Philip Suppelna, Andreas Mock, Mario Hlevnjak, Sabine Heublein, Eva Schumacher-Wulf, Andreas Schneeweiss
• Jahr: 2023
• Umfang: 8 S.
• Illustrationen: Illustrationen
• Fussnoten: Online veröffentlicht: 20. September 2023 ; Gesehen am 09.11.2023
• Titel Quelle: Enthalten in: Breast care
• Ort Quelle: Basel : Karger, 2006
• Jahr Quelle: 2023
• Band/Heft Quelle: (2023), Seite 1-8
• ISSN Quelle: 1661-3805
• DOI: doi:10.1159/000533902
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1869895584

Abstract

Background: Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug use. Here, we describe the current challenges and our experience with reimbursement of molecular therapies in mBC. Methods: A total of 100 applications for reimbursement of off-label therapies recommended by an iMTB were filed for patients with mBC, of which 89 were evaluable for this analysis. The approval rate was correlated with the molecular level of evidence of the respective therapy according to the National Center for Tumor Diseases (NCT) and European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) classification as well as with pretreatment therapy lines. Findings: Overall, 53.9% (48/89) of reimbursement applications were approved. Applications for therapies based on level of evidence m1 (NCT classification), tier I and II (ESCAT classification) had a significantly and clinically relevant increased chance of reimbursement, while a greater number of previous treatment lines had no significantly increased chance of approval, though a trend of approval toward higher treatment lines was detectable. Interpretation: Currently, the German jurisdiction seems to aggravate the clinical implementation of clinically urgently needed molecular therapies.